ABCL Stock Overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AbCellera Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.01 |
| 52 Week High | US$6.06 |
| 52 Week Low | US$2.34 |
| Beta | 0.35 |
| 11 Month Change | 10.26% |
| 3 Month Change | 20.40% |
| 1 Year Change | -35.13% |
| 33 Year Change | -77.70% |
| 5 Year Change | n/a |
| Change since IPO | -94.89% |
Recent News & Updates
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 07
AbCellera: A Platform To Pipeline Transition
Oct 14Recent updates
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 07AbCellera: A Platform To Pipeline Transition
Oct 14AbCellera: A Waiting Game With High Uncertainty
Aug 23Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
May 29AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11Shareholder Returns
| ABCL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 2.0% | 1.6% | 0.6% |
| 1Y | -35.1% | 4.0% | 31.9% |
Return vs Industry: ABCL underperformed the US Life Sciences industry which returned 4% over the past year.
Return vs Market: ABCL underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 8.8% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABCL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABCL's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 586 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
AbCellera Biologics Inc. Fundamentals Summary
| ABCL fundamental statistics | |
|---|---|
| Market cap | US$889.05m |
| Earnings (TTM) | -US$175.80m |
| Revenue (TTM) | US$32.96m |
27.0x
P/S Ratio-5.1x
P/E RatioIs ABCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABCL income statement (TTM) | |
|---|---|
| Revenue | US$32.96m |
| Cost of Revenue | US$169.81m |
| Gross Profit | -US$136.84m |
| Other Expenses | US$38.95m |
| Earnings | -US$175.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | -415.15% |
| Net Profit Margin | -533.33% |
| Debt/Equity Ratio | 0% |
How did ABCL perform over the long term?
See historical performance and comparison